ERBB2 and breast carcinoma: First, some factors that may lead to heterogeneity and thus have an influence on treatment outcome—such as treatment options (adjuvant and/or neoadjuvant chemotherapy), chemotherapeutic agents, breast cancer subtypes (hormone receptor-positive, Her2-positive, and triple-negative), and TNM staging status—were not strictly described in some studies.